Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic

Oren Gilad1, Barzin Y Nabet, Ryan L Ragland

  • 1Abramson Family Cancer Research Institute and Department of Cancer Biology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Cancer Research
|November 25, 2010
PubMed

Insights

The ATR-Chk1 pathway limits genomic instability from oncogenic Ras. Suppressing ATR causes synthetic lethality or promotes tumors, highlighting ATR as a cancer target.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cancer Research

Background:

  • Oncogenic stress activates the ATR-Chk1 pathway.
  • The ATR-Chk1 pathway's role in limiting genomic instability during oncogenic transformation is crucial.

Purpose of the Study:

  • To investigate the role of the ATR-Chk1 pathway in maintaining genomic stability under oncogenic Ras transformation.
  • To explore the consequences of ATR pathway inhibition or reduction in the context of oncogenic Ras.

Main Methods:

  • Quantification of genomic instability (chromatid breaks, sister chromatid exchanges, H2AX phosphorylation).
  • Assessment of synthetic lethality upon hypomorphic ATR reduction with oncogenic Ras.
  • Evaluation of tumor promotion in p53 heterozygous mice with ATR haploinsufficiency and K-ras(G12D) expression.

Main Results:

  • ATR pathway inhibition synergistically increased genomic instability with oncogenic Ras.
  • Hypomorphic ATR reduction was synthetic lethal with oncogenic Ras, independent of cell cycling.
  • ATR haploinsufficiency with K-ras(G12D) promoted lung adenocarcinoma, sarcoma, and lymphoma in mice, associated with deletions and p53 loss.

Conclusions:

  • ATR pathway reduction leads to distinct outcomes: synthetic lethality or tumor promotion, depending on the degree of suppression.
  • The ATR pathway is a critical barrier against malignant progression.
  • ATR pathway modulation presents a potential therapeutic strategy for cancers driven by oncogenic Ras.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...